Clinical Trial Update: Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

View source ↗

Summary

Clinical trial update describing an extended access program using lorcaserin to treat Dravet syndrome and other refractory epilepsies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Drug-resistant Epilepsy
• Myoclonic Epilepsy

Drugs mentioned

• Lorcaserin (lorcaserin)

Snippet

Sponsor: Eisai Inc. | Conditions: Epilepsies, Myoclonic, Drug Resistant Epilepsy | Status: AVAILABLE